Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)

Last updated: August 12, 2024
Sponsor: Organon and Co
Overall Status: Completed

Phase

3

Condition

Hypercholesterolemia

Dyslipidemia

Hypertriglyceridemia

Treatment

ezetimibe (+) simvastatin

Clinical Study ID

NCT00651560
0653A-148
2008_008
MK0653A-148
  • Ages > 18
  • All Genders

Study Summary

This study is intended to allow physicians to check the superior clinical efficacy of Vytorin compared to atorvastatin, as the most adequate therapy using the ATP-III goals achievement and cardiovascular risk reduction in adult patients with dislipidemia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients Who Voluntary Accept To Participate In The Study After Been Informed By TheDoctor And Signed The Informed Consent Form.

Exclusion

Exclusion Criteria:

  • Any Another Kind Of Contraindication For Use Of Statins

  • Hypersensitivity To Any Of The Active Ingredients

  • Increased Serum Hepatic Enzymes (Over 3 Times Only)

  • Patients With Severe Hepatic Insufficiency

  • Women who are Pregnant or Potentially Pregnant

Study Design

Total Participants: 167
Treatment Group(s): 1
Primary Treatment: ezetimibe (+) simvastatin
Phase: 3
Study Start date:
November 01, 2005
Estimated Completion Date:
December 23, 2005